Liver
MMaT-3 policy decreases survival, increases recurrence after transplant in HCC patients
WASHINGTON — The MELD score at transplant minus three points policy led to poor survival and recurrence outcomes after liver transplantation among patients with hepatocellular carcinoma, according to research at The Liver Meeting.
Black, Latino patients underrepresented in ‘high-impact’ cirrhosis clinical trials in US
WASHINGTON — Black and Latino patients are underrepresented in cirrhosis clinical trials, underpinning the need for systematic improvement, according to research presented at The Liver Meeting.
Liver transplant recipients gain up to 17 life-years from living donors vs. donor waitlist
A case-control study in JAMA Surgery revealed that patients with end-stage liver disease had a 34% reduction in mortality after living-donor liver transplantation compared with patients who remained on a wait list for a deceased donor.
Downstaging HCC to Milan criteria prior to liver transplant yield ‘excellent outcomes’
Researchers reported excellent 10-year outcomes among patients with hepatocellular carcinoma that was downstaged to within Milan criteria prior to liver transplant, according to a multicenter analysis published in JAMA Surgery.
NASH ‘fastest growing cause’ of liver cancer death worldwide
Despite global declines in liver cancer mortality attributed to hepatitis B and C, liver cancer mortality rose sharply in the Americas, driven by an increase in nonalcoholic steatohepatitis, according to data published in Cell Metabolism.
Rare germline mutations in CIDEB gene protect against liver disease, damage
In one of the largest exome-sequencing studies on liver health, researchers found rare genetic loss-of-function variants in the CIDEB gene were associated with significant protection from liver damage and disease.
Hepatologists, gastroenterologists lead NASH diagnosis yet ‘underdiagnosis’ persists
Gastroenterologists and hepatologists were leaders in nonalcoholic steatohepatitis diagnosis and viewed as primary coordinators of care, but the condition is still underdiagnosed and undertreated overall, noted data in BMC Gastroenterology.
VIDEO: ‘Critical to test’ for HBV, latent TB coinfection to reduce liver injury
In a Healio video exclusive, Harvey Kaufman, MD, senior medical director at Quest Diagnostics, highlighted the need for concurrent hepatitis B and latent tuberculosis testing to mitigate the risk for drug-induced liver injury.
Q&A: Noninvasive liquid biopsy test could be ‘game changer’ for NASH, liver fibrosis
A noninvasive liquid biopsy test diagnosed the presence and severity of nonalcoholic steatohepatitis and liver fibrosis more reliably than liver biopsy, according to research published in Gut.